The 'Everything Vaccine' Gamble: Can One Shot Protect Against Multiple Diseases?

In May 2025, the U.S. Department of Health and Human Services and the National Institutes of Health announced the "Generation Gold Standard" initiative — a $500 million program to develop universal vaccines against pandemic-prone viruses including H5N1 avian influenza, SARS-CoV-2, SARS-CoV-1, and MERS-CoV [1]. Clinical trials for universal influenza vaccines under this program are scheduled to begin in 2026, with FDA approval targeted for 2029 [1].

The announcement crystallized a broader scientific push that has been building for years: the pursuit of so-called "everything vaccines" — single injections designed to train the immune system against multiple structurally distinct pathogens simultaneously. The idea is seductive. Instead of annual flu shots, updated COVID boosters, and separate RSV immunizations, a patient could receive one dose covering several threats at once. But the gap between that vision and the biological, regulatory, and economic realities is wide — and the history of broad-spectrum vaccine development is littered with expensive failures.

Where the Science Stands

The clinical pipeline for broad-spectrum vaccines is active but early-stage. Across platforms tracked by WHO, ClinicalTrials.gov, and company disclosures, roughly 85 candidates remain in preclinical development, with 18 in Phase I trials, 12 in Phase I/II, 8 in Phase II, and 5 in Phase III [2]. None have been approved.

Source: WHO, ClinicalTrials.gov, company pipelines

Data as of Mar 1, 2026CSV

Moderna is the furthest along in the combination respiratory virus space. Its mRNA-1083 candidate — a two-in-one flu and COVID shot — has produced positive Phase III data in a trial of more than 40,000 adults aged 50 and above [3]. The company is also developing a triple-target shot against flu, COVID, and RSV [3]. Pfizer and BioNTech are running a late-stage trial for their own flu-COVID combination [3].

Beyond respiratory viruses, BioNTech's BNT164a1/BNT164b1 is the only multi-antigen mRNA tuberculosis vaccine to have entered clinical trials, with Phase I/II studies launched in April 2023 in Germany and South Africa, with completion expected in 2027 [4]. Moderna's mRNA-1653 targets both human metapneumovirus and parainfluenza virus, with Phase I results showing robust neutralizing antibody responses [4]. And Osivax's OVX836 — a broad-spectrum influenza A candidate targeting the conserved nucleoprotein — received $19.5 million from BARDA to advance development [5].

The NIH's own BPL-1357 and BPL-24910 candidates, developed in-house under the Generation Gold Standard initiative, are intranasal vaccines designed to block virus transmission at the respiratory entry point. The platform is fully government-owned and could theoretically be adapted for RSV, metapneumovirus, and parainfluenza [1].

How One Shot Can Target Many Pathogens

Two primary platform technologies underpin most broad-spectrum vaccine candidates: mRNA-lipid nanoparticle systems and self-assembling protein nanoparticles.

mRNA vaccines work by encoding instructions for the body to produce specific viral proteins, which then trigger an immune response. Because the mRNA sequence can be swapped relatively easily, a single lipid nanoparticle delivery system can carry instructions for antigens from multiple pathogens [4]. This modularity is what allows Moderna to combine flu and COVID antigens in one shot.

Mosaic nanoparticle vaccines take a different approach. Using a molecular conjugation system called SpyTag/SpyCatcher, researchers can attach multiple different viral receptor-binding domains to the surface of a single protein nanoparticle [6]. A SpyCatcher protein fused to the nanoparticle scaffold forms a spontaneous covalent bond with a small SpyTag peptide attached to each antigen — allowing up to eight distinct antigens to be displayed on one particle [7].

The immunological logic is that B cells with receptors recognizing conserved regions shared across multiple virus strains are preferentially stimulated by these mosaic displays through avidity effects [6]. In mouse studies, mosaic nanoparticles displaying receptor-binding domains from SARS-CoV-2 alongside RBDs from multiple animal betacoronaviruses elicited antibodies with "superior cross-reactive recognition" compared to particles displaying only SARS-CoV-2 antigens [6]. Caltech and collaborators have developed "Quartet Nanocages" co-displaying antigens from four different coronaviruses, with results published in Nature Nanotechnology [8].

But there are ceiling limits. Each additional antigen competes for space on the nanoparticle surface and for immune system attention. The more targets included, the greater the risk that the immune response to each individual component is diluted — a concern that critics of the broad-spectrum approach have raised repeatedly.

The Dilution Question: Does One Shot Mean Weaker Protection?

The central scientific criticism of everything vaccines is straightforward: by asking the immune system to respond to multiple unrelated antigens simultaneously, you may get a weaker response to each one than a purpose-built, single-target vaccine would produce.

The evidence so far is mixed. Moderna's Phase III data for mRNA-1083 showed that its combination flu-COVID shot was "more effective than existing shots" in head-to-head comparisons — meaning participants who received the combo generated immune responses to both flu and COVID that were non-inferior to, or exceeded, responses from separate standard vaccines [9]. This is the strongest clinical evidence to date that immune dilution is not inevitable.

However, the history of combination vaccines includes notable dilution effects. A study analyzing VAERS data for hepatitis A vaccine (Havrix), hepatitis B vaccine (Engerix-B), and the combination vaccine (Twinrix) found 46, 69, and 82 adverse events significantly associated with each product respectively — suggesting the combination product had a distinct, and in some ways broader, adverse event profile [10]. While adverse events are not the same as reduced efficacy, the finding illustrates how combining antigens can produce unexpected immunological interactions.

Current influenza vaccines — which are already multivalent, targeting three or four strains per season — offer a cautionary reference point. Their efficacy fluctuates between 10% and 60% annually depending on strain match [11]. During the 2014–2015 season, antigenic drift in circulating H3N2 viruses reduced vaccine effectiveness to just 6% against that strain, with overall efficacy of only 19% [11]. The more strains targeted, the more variables that can go wrong.

Research Momentum

Academic interest in broad-spectrum vaccines has surged. According to OpenAlex, the number of published research papers on the topic rose from roughly 1,900 in 2011 to a peak of over 16,000 in 2024 — an eightfold increase driven largely by the COVID-19 pandemic [12]. That output has since declined, with approximately 3,800 papers published so far in 2026, possibly reflecting both a return to baseline and the effects of reduced pandemic-era funding.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Following the Money

Public funding for broad-spectrum vaccine research is substantial but fragmented — and politically vulnerable.

The NIH's $500 million Generation Gold Standard program represents the single largest commitment [1]. CEPI, the Coalition for Epidemic Preparedness Innovations, has invested up to $286 million (Canadian) in broadly protective coronavirus vaccine programs since 2021, including a $24 million grant to VIDO at the University of Saskatchewan for its pan-sarbecovirus vaccine [13]. CEPI also committed $54.3 million to support a Phase III trial for Moderna's H5 pandemic influenza vaccine candidate, set to begin in early 2026 [14].

Source: CEPI, BARDA, NIH press releases

Data as of Mar 1, 2026CSV

But the funding picture is unstable. In 2025, HHS cancelled 22 BARDA-funded mRNA vaccine contracts totaling $500 million as part of a policy shift away from mRNA platforms [15]. CEPI stepped in to fund Moderna's H5 Phase III trial after U.S. government support was pulled [14]. This creates a paradox: broad-spectrum vaccine development depends on sustained, long-term funding, but the political winds that govern that funding can shift within a single budget cycle.

Compared to single-pathogen vaccine development — where individual programs like Pfizer's Prevnar 20 (pneumococcal) or Merck's Gardasil 9 (HPV) each attracted billions in private investment — broad-spectrum candidates are still largely dependent on public and philanthropic money. The commercial model is unproven because no broad-spectrum vaccine has reached market.

Who Gets Access?

If broad-spectrum vaccines do reach approval, pricing and distribution will determine whether they reduce or widen global health inequities.

Gavi, the Vaccine Alliance, has immunized over 760 million children in low-income countries by pooling demand and negotiating procurement prices — for instance, securing pneumococcal vaccine doses at a maximum of $2.90 each [16]. But Gavi's model is built around negotiating prices for individual vaccines. A single broad-spectrum shot covering multiple diseases could disrupt this framework entirely.

If a combination vaccine targeting flu, COVID, and RSV is priced as a premium product — reflecting R&D costs for a multi-target platform — it may cost more per dose than the sum of the individual vaccines it replaces. Low- and middle-income countries that currently negotiate tiered pricing for each pathogen separately would face a new and potentially more expensive procurement challenge [17].

Most vaccine manufacturers apply tiered pricing policies, charging higher-income countries more and offering discounts to lower-income nations [17]. But these arrangements have historically been negotiated on a per-product basis. A vaccine covering three diseases simultaneously could complicate these negotiations if manufacturers argue the product delivers three vaccines' worth of value.

Gavi-eligible countries — those with GNI per capita below $1,730 — could be left waiting years for access while wealthier nations absorb initial supply [16]. The COVAX experience during COVID-19, where high-income countries secured early vaccine supplies through bilateral deals while lower-income nations waited, is a recent and painful precedent.

Regulatory Frameworks Are Not Ready

Current regulatory pathways were designed to evaluate vaccines against one disease at a time. A vaccine claiming to prevent influenza, COVID-19, and RSV simultaneously presents a novel challenge: how do you design a clinical trial that adequately demonstrates efficacy against each target?

The FDA's Center for Biologics Evaluation and Research reviews vaccine applications, and the EMA handles approvals across the European Economic Area [18]. Both agencies have experience with multivalent vaccines — quadrivalent flu shots, for example — but these target variants of a single pathogen, not structurally distinct diseases.

For multi-disease vaccines, regulators would need to define: how many endpoints are required? Must the vaccine demonstrate non-inferiority to existing best-in-class vaccines for each disease separately? What happens if it excels against two targets but underperforms against a third?

During COVID-19, both agencies adopted accelerated review mechanisms, including rolling reviews and parallel trial steps [18]. The EMA published draft guidelines on mRNA vaccine quality requirements that address some platform-level concerns [19]. But neither the FDA nor EMA has published a formal approval pathway specifically designed for multi-disease combination vaccines using novel platforms.

The WHO, which issues prequalification for vaccines used in Gavi-supported countries, faces similar gaps. Prequalification standards are disease-specific, and adapting them for a broad-spectrum product would require new technical guidelines — a process that takes years.

Historical Precedent: The Universal Flu Vaccine Problem

The most instructive historical parallel is the decades-long quest for a universal influenza vaccine. Researchers have pursued this goal since at least the 1940s, when a flu vaccine given to U.S. soldiers during World War II failed [11]. The 1957 Asian Flu pandemic saw 40 million vaccine doses deployed with what officials described as "no appreciable effect" [11]. The 1976 swine flu vaccination program was halted after a wave of Guillain-Barré syndrome cases [11].

More recently, BiondVax's M-001 universal flu vaccine candidate showed promising immunogenicity in Phase II trials, but its Phase III study, published in October 2020, showed no efficacy [11]. Over 40 universal influenza vaccine candidates remain in development, but none has reached approval after more than 80 years of effort [11].

Defenders of current broad-spectrum efforts argue the technology has fundamentally changed. mRNA platforms allow rapid antigen redesign. Mosaic nanoparticles can present conserved epitopes in ways that previous protein-based approaches could not. The SpyTag/SpyCatcher system enables modular assembly that was not available even a decade ago [6]. The NIH's intranasal BPL platform targets mucosal immunity — blocking transmission at the point of entry rather than relying solely on systemic antibody responses [1].

These are real technical advances. But the underlying biological challenge — training the immune system to recognize and respond effectively to highly variable or structurally diverse pathogens — has not changed. Viral mutation, antigenic drift, and immune imprinting (where prior exposures shape and sometimes limit future responses) remain formidable obstacles.

Liability and Adverse Event Attribution

If a broad-spectrum vaccine causes an adverse event, determining which antigen component is responsible presents a novel legal and scientific problem.

In the United States, the National Vaccine Injury Compensation Program (VICP), established under the 1986 National Childhood Vaccine Injury Act, provides a no-fault system for resolving vaccine injury claims [10]. The Vaccine Adverse Event Reporting System (VAERS) tracks post-market safety signals [20]. But both systems were designed around vaccines targeting single diseases or closely related strains.

Causality assessment for vaccine adverse events is already difficult. Local reactions can be attributed with some confidence, but delayed adverse events are hard to correlate with specific antigens [21]. The standard tools for determining drug causality — stopping the medication and observing resolution, or re-challenging — do not apply to one-time vaccine administrations [21].

For a vaccine containing antigens for influenza, COVID-19, and RSV, a reported adverse event could theoretically be caused by any one of the three antigen components, the delivery platform itself, or interactions between components. Existing pharmacovigilance systems are not designed to disaggregate causality at this level of complexity.

In the EU, the marketing authorization holder bears liability for product defects, but the legal definition of "defect" in a multi-disease vaccine — where one component might meet safety thresholds while another does not — is untested [18]. The WHO's causality assessment algorithm for adverse events following immunization has been criticized for insufficient granularity even for single-antigen products [21].

The Steelman Case for Skepticism

The strongest case against everything vaccines is not that they are impossible, but that they are being oversold relative to the evidence.

No broad-spectrum vaccine targeting structurally distinct diseases has been approved. The closest comparators — multivalent flu vaccines — have efficacy that remains mediocre after decades of refinement. The single most-cited success so far, Moderna's mRNA-1083, combines two respiratory viruses on the same platform, which is a meaningful achievement, but not the same as a universal vaccine against unrelated pathogens.

The funding landscape is precarious. The cancellation of $500 million in BARDA mRNA contracts demonstrates that political support for these programs can evaporate quickly [15]. And the commercial incentive structure is unclear: pharmaceutical companies invest heavily in products with defined markets, but a vaccine that replaces three separate revenue streams could cannibalize existing product lines.

Meanwhile, single-pathogen vaccines continue to improve. Updated COVID-19 boosters, new RSV vaccines for older adults and infants, and next-generation flu vaccines all offer incremental but concrete benefits that broad-spectrum candidates have not yet matched in clinical data [22].

The broad-spectrum vaccine field is producing genuine scientific advances in antigen design, delivery platforms, and immunological understanding. Whether those advances translate into approved products that are affordable, accessible, and more effective than the alternatives they aim to replace remains an open question — one that will take years of rigorous clinical trials, regulatory innovation, and equitable distribution planning to answer.